Lancet: Is it necessary to screen the "female killer" ovarian cancer population?

Ovarian cancer is the third most common malignant tumor of the female medsci.

All previous trials have used a combination of biomarker CA125, transvaginal ultrasound (TVS), and pelvic imaging for early screening of ovarian cancer.

In a multicenter randomized trial (UKCTOCS), the researchers randomly assigned 202,638 women to two annual screening groups-multimodal screening (MMS: longitudinal CA125 + second-line TVS) and ultrasound Screening (USS: TVS first and second-line screening), and a non-screening group.

So, what are the follow-up results of this trial? Can population screening reduce deaths caused by the disease? To this end, UKCTOCS recently in " The Lancet on" Lancet magazine published the results of ovarian cancer mortality after long-term follow-up.

In this randomized controlled trial, researchers recruited 50-74-year-old postmenopausal women from 13 National Health Service Trust Centers in England, Wales and Northern Ireland.

Experimental flowchart

From April 17, 2001 to September 29, 2005, a total of 1,243,282 women were included, and 202,562 were included in the analysis: 50,625 (25.

The median follow-up time was 16±3 years (IQR 15±1–17±3), and a total of 2055 women were diagnosed with fallopian tube cancer or ovarian cancer.

Compared with unscreened, cancers found in the MMS group were more early.

Cumulative incidence of all ovarian cancer and fallopian tube cancer (A) and aggressive epithelial ovarian cancer and fallopian tube cancer (B)

Further analysis found that a total of 1206 women died of ovarian cancer and fallopian tube cancer, and there was no significant difference in survival benefit between the three groups: 296 (0.

references:

Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.